Study Name:
EFC15858
Targeted Disease(s):
Lung Cancer
Purpose of Study:
Randomized, Open Label Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated Metastatic Non- Squamous Non-Small Cell Lung Cancer Patients With CEACAM5 Positive Tumors
Study Dates:
February 6, 2020 - April 10, 2024
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Lead Institution:
Sarah Cannon Research Institute
Funding Source:
Sanofi
Sponsors:
Sanofi
ClinicalTrails.gov Identifier:
NCT04154956
